MREO241220C4000
- 0.20
- -0.05-20.00%
Mereo BioPharma Newsroom
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating
Baird Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $8
Mereo BioPharma Group Analyst Ratings
Buy Rating Affirmed for Mereo Biopharma on Strong Financials and Promising Pipeline Progress
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Mereo Biopharma on Strong Clinical and Financial Prospects
Mereo BioPharma Group Analyst Ratings
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo BioPharma Group Analyst Ratings
Mereo BioPharma Group Analyst Ratings
Mereo BioPharma Group Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (LUCY), Rockwell Med (RMTI) and Mereo Biopharma Group Plc (MREO)
Mereo BioPharma Group Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)
Strong Buy Rating for Mereo Biopharma on Setrusumab's Promising Phase 3 Progress and Financial Outlook
Mereo Biopharma Group Plc: A Buy Rating Backed by Strong Leadership and Promising Drug Pipeline